Association of hypertension with symptoms of benign prostatic hyperplasia

被引:115
作者
Michel, MC
Heemann, U
Schumacher, H
Mehlburger, L
Goepel, M
机构
[1] Univ Amsterdam, Dept Pharmacol & Pharmacotherapy, Amsterdam, Netherlands
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Nephrol, D-8000 Munich, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Klinikum Niederberg, Dept Urol, Velbert, Germany
关键词
aging; prostatic hyperplasia; epidemiology; hypertension;
D O I
10.1097/01.ju.0000139995.85780.d8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We determined whether the intensity of benign prostatic hyperplasia (BPH) symptoms and arterial hypertension are associated. Materials and Methods: Baseline data from a large sample of men seeking treatment for BPH symptoms were analyzed retrospectively. BPH symptom intensity (assessed by the International Prostatic Symptom Score [I-PSS] or urinary flow rate [Q(max)]) and blood pressure were determined in 9,857 patients with BPH. Normotension was defined as a diastolic blood pressure of 90 mm Hg or less, the absence of the diagnosis hypertension and the lack of antihypertensive medication (in 4,725). Hypertension was concomitantly defined as a diastolic blood pressure of greater than 90 mm Hg (in 1,727), being diagnosed with hypertension (1,950) or the current prescription of anti-hypertensive drugs (3,360 patients). Results: When age and presence of hypertension were used as the independent explanatory variables, each year of age contributed 0.13 points and measured hypertension 1.60 points to I-PSS as the dependent response variable. Similar results were obtained with Q(max) as the dependent response variable. In a logistic regression procedure using age, I-PSS and Q(max). as the independent explanatory variables, each year of age and each I-PSS point significantly increased the risk of being hypertensive by 5.3% and 5.0%, respectively, while Q(max) did not yield a statistically significant contribution to that risk. Conclusions: We conclude that a significant, age independent association exists between BPH symptoms and hypertension. This finding indicates a common pathophysiological factor for both disease states such as increased sympathetic activity.
引用
收藏
页码:1390 / 1393
页数:4
相关论文
共 19 条
[1]  
Bourke J B, 1966, Br J Urol, V38, P18, DOI 10.1111/j.1464-410X.1966.tb09675.x
[2]  
BOYLE P, 1995, SCAND J UROL NEPHROL, P7
[3]   Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia [J].
Debruyne, FMJ ;
Jardin, A ;
Colloi, D ;
Resel, L ;
Witjes, WPJ ;
Delauche-Cavallier, MC ;
McCarthy, C ;
Geffriaud-Ricouard, C .
EUROPEAN UROLOGY, 1998, 34 (03) :169-175
[4]  
Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967
[5]  
GLYNN RJ, 1985, AM J EPIDEMIOL, V121, P78
[6]   PLASMA-CATECHOLAMINES AND ESSENTIAL-HYPERTENSION - AN ANALYTICAL REVIEW [J].
GOLDSTEIN, DS .
HYPERTENSION, 1983, 5 (01) :86-99
[7]   Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial [J].
Kirby, RS ;
Roehrborn, C ;
Boyle, P ;
Bartsch, G ;
Jardin, A ;
Cary, MM ;
Sweeney, M ;
Grossman, EB .
UROLOGY, 2003, 61 (01) :119-126
[8]   Epidemiology of risk factors for hypertension - Implications for prevention and therapy [J].
Kornitzer, M ;
Dramaix, M ;
De Backer, G .
DRUGS, 1999, 57 (05) :695-712
[9]   The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia [J].
Lepor, H ;
Williford, WO ;
Barry, MJ ;
Brawer, MK ;
Dixon, CM ;
Gormley, G ;
Haakenson, C ;
Machi, M ;
Narayan, P ;
Padley, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (08) :533-539
[10]   Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms:: Does co-morbidity alter tolerability? [J].
Michel, MC ;
Mehlburger, L ;
Bressel, HU ;
Schumacher, H ;
Schäfers, RF ;
Goepel, M .
JOURNAL OF UROLOGY, 1998, 160 (03) :784-791